186 related articles for article (PubMed ID: 20169510)
21. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents.
Mehta R; Parameswaran R; Shapiro AD
Haemophilia; 2006 Dec; 12 Suppl 6():54-61. PubMed ID: 17123395
[TBL] [Abstract][Full Text] [Related]
22. Views on methods for monitoring recombinant factor VIIa in inhibitor patients.
Key NS; Nelsestuen GL
Semin Hematol; 2004 Jan; 41(1 Suppl 1):51-4. PubMed ID: 14872422
[TBL] [Abstract][Full Text] [Related]
23. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
[TBL] [Abstract][Full Text] [Related]
24. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
Monahan PE; Aledort LM;
Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804
[TBL] [Abstract][Full Text] [Related]
25. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor.
Hayashi T; Tanaka I; Shima M; Yoshida K; Fukuda K; Sakurai Y; Matsumoto T; Giddings JC; Yoshioka A
Haemophilia; 2004 Jul; 10(4):397-400. PubMed ID: 15230956
[TBL] [Abstract][Full Text] [Related]
26. Use of recombinant factor VIIa (NovoSeven) in a haemophilia A patient with inhibitor in Kuwait.
Kanyike FB; Abdul-Salam SA; Prakash B; Sharhan A; Wahib N; Youssef AH
Haemophilia; 1999 Jul; 5(4):273-5. PubMed ID: 10469183
[TBL] [Abstract][Full Text] [Related]
27. Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors.
Teitel JM
Transfus Apher Sci; 2018 Aug; 57(4):466-471. PubMed ID: 30093246
[TBL] [Abstract][Full Text] [Related]
28. Toward optimal therapy for inhibitors in hemophilia.
Kempton CL; Meeks SL
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):364-71. PubMed ID: 25696880
[TBL] [Abstract][Full Text] [Related]
29. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
Steen Carlsson K; Astermark J; Donfield S; Berntorp E
Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509
[TBL] [Abstract][Full Text] [Related]
30. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
Holme PA; Brosstad F; Tjønnfjord GE
Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms and monitoring of bypassing agent therapy.
Hoffman M; Dargaud Y
J Thromb Haemost; 2012 Aug; 10(8):1478-85. PubMed ID: 22632160
[TBL] [Abstract][Full Text] [Related]
32. Treatment of an acquired factor VIII inhibitor with sequential recombinant factor VIIa and FEIBA.
Miranda GG; Rodgers GM
Haemophilia; 2009 Jan; 15(1):383-5. PubMed ID: 18759746
[No Abstract] [Full Text] [Related]
33. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
34. New approaches in the management of inhibitor patients.
Young G
Acta Haematol; 2006; 115(3-4):172-9. PubMed ID: 16549892
[TBL] [Abstract][Full Text] [Related]
35. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
[TBL] [Abstract][Full Text] [Related]
36. In silico prediction of FVIII epitopes recognised by natural autoantibodies in polyvalent immunoglobulin concentrates.
Di Giambattista M; Branckaert T; Hougardy V; Kemball-Cook G; Laub R
Mol Immunol; 2007 Mar; 44(8):1903-13. PubMed ID: 17113150
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic decision-making in inhibitor patients.
Allen G; Aledort L
Am J Hematol; 2006 Jan; 81(1):71-2. PubMed ID: 16369965
[TBL] [Abstract][Full Text] [Related]
38. Treatment of factor VIII inhibitors.
Sultan Y; Algiman M
Blood Coagul Fibrinolysis; 1990 Jun; 1(2):193-9. PubMed ID: 2130931
[TBL] [Abstract][Full Text] [Related]
39. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.
Ingerslev J; Sørensen B
Br J Haematol; 2011 Oct; 155(2):256-62. PubMed ID: 21895627
[TBL] [Abstract][Full Text] [Related]
40. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
Meili EO; Dazzi H; von Felten A
Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
